Company: IMRX
Filing Date: 2025-09-08
Form Type: 424B3
Source: 0001104659-25-088317
Chunk: 9

Company: Immuneering Corp
Filing Date: 2025-09-08
Form: 424B3
Chunk 9
---
 common stock in all respects, except that the holders of our Class B common stock are not entitled to vote on shareholder matters except as required by law. In addition, holders of our Class B common stock have the right to convert each share of Class B common stock into one share of Class A common stock at the holder’s election, unless, as a result of such conversion, the holder and its affiliates would own more than 9.9% of the combined voting power of our outstanding share capital, and subject to certain additional restrictions as more particularly described in our Certificate of Incorporation. Shares of Class B common stock, once converted to shares of Class A common stock, may not be converted back into shares of Class B common stock.

#### Preferred Stock
Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class A common stock. The issuance of our preferred stock could adversely affect the voting power of holders of Class A common stock and the likelihood that such holders, including the holders of Class B common stock,

<div align='center'>8</div>

TABLE OF CONTENTS

will receive payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Warrants Pre-Funded Warrants On August 21, 2025, we entered into a securities purchase agreement with certain purchasers named therein, pursuant to which we agreed to sell securities to such purchasers in a private placement. In the private placement, the purchasers had the option to purchase either shares of our Class A common stock or, in lieu thereof, pre-funded warrants, or the Pre-Funded Warrants, to purchase shares of our Class A common stock, each with an exercise price of $0.001 per share. Accordingly, we issued Pre-Funded Warrants to purchase 1,077,764 shares of our Class A common stock upon the closing of the private placement. As of September 2, 2025, Pre-Funded Warrants to purchase an aggregate of 1,077,764